• Sagimet Biosciences director George Kemble sold 18,844 shares of Series A Common Stock on July 20, 2026.
• Sale priced at USD 7.46 per share on a weighted-average basis.
• He reported 62,161 shares owned following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-312386), on July 22, 2026, and is solely responsible for the information contained therein.